ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Kidney transplantation"

  • 2015 American Transplant Congress

    Pubertal Development in Pediatric Kidney Transplant Patients Receiving Everolimus Or Conventional Immunosuppression

    L. Pape,1 T. Ahlenstiel-Grunow,1 A. Zapf,2 M. Mynarek,3 J. Förster.1

    1Pediatric Nephrology, Hannover Medical School, Hannover, NDS, Germany; 2Medical Statistics, University Medical Center Göttingen, Göttingen, NDS, Germany; 3Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

    TOR inhibitors (mTORi) have been discussed to eventually influence pubertal development after pediatric kidney transplantation (Tx).This is the first trial to compare pubertal development in…
  • 2015 American Transplant Congress

    Incidence and Characteristics of CMV Infection in High Risk (D+R-) Kidney Transplant Recipients and the Utility of Monthly Surveillance After Routine Prophylaxis

    M. Bhattarai, C. Puttarajappa, G. Mour, C. Wu, P. Sood, N. Shah, R. Mehta, A. Tevar, S. Hariharan.

    Internal Medicine, University of Pittsburgh, Pittsburgh, PA.

    Cytomegalovirus (CMV) infection is the most common opportunistic viral infection after renal transplantation. Optimal duration of antiviral prophylaxis and the role of post prophylaxis surveillance…
  • 2015 American Transplant Congress

    ABO-Incompatible Live Donor Kidney Transplants Inferior to ABO-Compatible Transplants, but Match Deceased Donor Results: Is Kidney Paired Donation the Answer?

    J. Verbesey, M. Cooper, A. Gilbert, M. Grafals, P. Weems, J. Moore, S. Ghasemian, C. Nilubol, B. Javaid.

    Georgetown University School of Medicine, MedStar Georgetown Transplant Institute, Kidney and Pancreas Transplant Program, Washington, DC.

    Objective: Compare kidney allograft survival in ABO-incompatible (ABO-I) and ABO-compatible (ABO-C) live donor kidney transplant recipients.Methods: We analyzed UNOS database for patients who underwent a…
  • 2015 American Transplant Congress

    Microvascular Inflammation in Early Protocol Biopsies of Renal Allografts in Cases of Chronic Active Antibody-Mediated Rejection

    T. Tsuji,1 M. Yanai,1 H. Itami,1 Y. Ishii,1 M. Akimoto,1 N. Fukuzawa,2 H. Harada,2 Y. Fukasawa.1

    1Demartment of Pathology, Sapporo City General Hospital, Sapporo, Japan; 2Department of Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Japan.

    Aim:Chronic active antibody-mediated rejection (chronic ABMR) is one important cause of late-stage renal allograft loss. However, few reports have used protocol biopsy to observe changes…
  • 2015 American Transplant Congress

    Pretransplant Antibodies Against Angiotensin II Type 1 Receptor in Renal Transplantation: Preliminary Data from the KNOW-KT Study

    K. Huh,1 J. Lee,1 Y. Park,2 Y. Kim,1 C. Ahn.3

    1Department of Transplantation Surgery, Yonsei University Health System, Seoul, Republic of Korea; 2Department of Laboratory Medicine, Yonsei University Health System, Seoul, Republic of Korea; 3Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.

    BackgroundThe antibodies (Abs) against angiotensin II type 1 receptor (AT1R) have been suggested as a risk factor for graft failure and acute rejection. However, incidence…
  • 2015 American Transplant Congress

    Quantifying the Survival Benefit of HLA-Incompatible Kidney Transplantation: A Multi-Center Study

    B. Orandi, X. Luo, A. Massie, J. Garonzik-Wang, B. Lonze, R. Ahmed, K. Van Arendonk, R. Montgomery, D. Segev.

    Surgery, Hopkins, Baltimore, MD.

    A single center study has demonstrated a two-fold survival benefit of incompatible live donor kidney transplant (ILDKT) compared to remaining on dialysis. We sought to…
  • 2015 American Transplant Congress

    Umbilical Vein Catheter Versus Double J Stent for Ureteric Anastomosis in Renal Transplantation: A Single Centre, Open Label, Randomized Trial

    V. Swaroop, A. Pereira, S. Smith, O. Masood, R. Pararajasingam, T. Augustine, H. Riad, S. Mehra, A. Tavakoli.

    Transplant Surgery, Manchester Royal Infirmary, Manchester, United Kingdom.

    Introduction: Double J (DJ) stents are used routinely in renal transplantation to prevent ureteric complications. A recent Cochrane review of literature showed that routine prophylactic…
  • 2015 American Transplant Congress

    Propensity Score-Weighted Analysis of Induction Therapies in Live Donor Kidney Transplantation in Modern Immunosuppression Era

    B. Tanriover,1 S. Zhang,2 M. MacConmara.3

    1Medicine, UTSW, Dallas, TX; 2Clinical Sciences, UTSW, Dallas, TX; 3Surgery, UTSW, Dallas, TX.

    Background: Induction therapy with interleukin-2 receptor antagonist (IL2-RA) is recommended as a first line agent in living donor renal transplantation (LRT). However, use of IL2-RA…
  • 2015 American Transplant Congress

    Final Results from the BENEFIT-EXT Trial: A 7 Year Follow-Up of Belatacept Treated Patients

    S. Florman,1 J. Medina Pestana,2 M. Rial,3 L. Rostaing,4 D. Kuypers,5 F. Mühlbacher,6 M. Polinsky,7 U. Meier-Kriesche,7 J. Grinyó,8 A. Durrbach.9

    1Mt Sinai Med Ctr, NY; 2Hosp do Rim e Hipertensão, Sao Paulo, Brazil; 3Inst de Nefrologia, Buenos Aires, Argentina; 4Univ Hospital, Toulouse, France; 5Univ Hospital Leuven, Leuven, Belgium; 6Vienna Transplantation Ctr, Vienna, Austria; 7BMS, Lawrenceville; 8Univ Hosp Bellvitge, Barcelona, Spain; 9Univ Hosp of Bicêtre, Villejuif, France.

    Background: At 3 and 5yrs post-transplant, BENEFIT-EXT showed a renal function benefit and consistent safety in belatacept (bela) treated pts vs cyclosporine (CsA). Final 7…
  • 2015 American Transplant Congress

    The C1q-Binding Assays and Clinical Outcomes in Kidney Transplantation

    P. Amico,1 G. Hönger,1 H. Hopfer,2 R. Liwski.3

    1Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland; 2Institute for Pathology, University Hospital Basel, Basel, Switzerland; 3Department of Pathology and Laboratory Medicine, Dalhousie University, Halifax, Canada.

    Background: Contradictory conclusions have emerged from clinical trials when testing the predictive value of C1q-binding donor-specific HLA-antibodies (HLA-DSA). The aim of this study was to…
  • « Previous Page
  • 1
  • …
  • 493
  • 494
  • 495
  • 496
  • 497
  • …
  • 531
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences